435 related articles for article (PubMed ID: 26996405)
21. An unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitis.
Lorefice L; Fenu G; Cabras F; Frau J; Coghe GC; Loi L; Marrosu MG; Cocco E
Mult Scler Relat Disord; 2016 May; 7():65-7. PubMed ID: 27237760
[TBL] [Abstract][Full Text] [Related]
22. Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
Zecca C; Antozzi CG; Torri Clerici V; Ferrazzini M; Mantegazza RE; Rossi S; Gobbi C
Acta Neurol Scand; 2018 Jun; 137(6):623-625. PubMed ID: 29205270
[TBL] [Abstract][Full Text] [Related]
23. Effects of dimethyl fumarate on lymphocyte subsets.
Berkovich R; Weiner LP
Mult Scler Relat Disord; 2015 Jul; 4(4):339-41. PubMed ID: 26195053
[TBL] [Abstract][Full Text] [Related]
24. Eosinophilic fasciitis-like disorder developing in the setting of multiple sclerosis therapy.
Sheu J; Kattapuram SV; Stankiewicz JM; Merola JF
J Drugs Dermatol; 2014 Sep; 13(9):1144-7. PubMed ID: 25226017
[TBL] [Abstract][Full Text] [Related]
25. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
Dorman E; Kansal AR; Sarda S
J Med Econ; 2015; 18(12):1085-91. PubMed ID: 26390149
[TBL] [Abstract][Full Text] [Related]
26. The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis.
Wicks P; Rasouliyan L; Katic B; Nafees B; Flood E; Sasané R
BMC Res Notes; 2016 Sep; 9(1):434. PubMed ID: 27604188
[TBL] [Abstract][Full Text] [Related]
27. [Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis].
Popova EV; Boyko AN; Orlova EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):68-72. PubMed ID: 28139614
[TBL] [Abstract][Full Text] [Related]
28. Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with multiple sclerosis.
Borrelli S; Mathias A; Goff GL; Pasquier RD; Théaudin M; Pot C
Mult Scler Relat Disord; 2022 Jul; 63():103887. PubMed ID: 35636269
[TBL] [Abstract][Full Text] [Related]
29. Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate.
O'Gorman J; Russell HK; Li J; Phillips G; Kurukulasuriya NC; Viglietta V
Clin Ther; 2015 Jul; 37(7):1402-1419.e5. PubMed ID: 25999183
[TBL] [Abstract][Full Text] [Related]
30. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
31. Multiple sclerosis: Dimethyl fumarate is coming of age.
Tintoré M; Sastre-Garriga J
Nat Rev Neurol; 2016 Aug; 12(8):436-7. PubMed ID: 27448183
[No Abstract] [Full Text] [Related]
32. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
[TBL] [Abstract][Full Text] [Related]
33. Fingolimod Prescribed for the Treatment of Multiple Sclerosis in Patients Younger Than Age 18 Years.
Fragoso YD; Alves-Leon SV; Barreira AA; Callegaro D; Brito Ferreira ML; Finkelsztejn A; Gomes S; Magno Goncalves MV; Moraes Machado MI; Marques VD; Cunha Matta AP; Papais-Alvarenga RM; Apostolos Pereira SL; Tauil CB
Pediatr Neurol; 2015 Aug; 53(2):166-8. PubMed ID: 26026897
[TBL] [Abstract][Full Text] [Related]
34. Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
[TBL] [Abstract][Full Text] [Related]
35. Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis.
Boullosa-Lale S; González-Freire L; Martínez-Martínez L; Crespo-Diz C
Farm Hosp; 2020 Dec; 45(2):73-76. PubMed ID: 33709887
[TBL] [Abstract][Full Text] [Related]
36. Severe disease exacerbation in a patient with neuromyelitis optica spectrum disorder during treatment with dimethyl fumarate.
Popiel M; Psujek M; Bartosik-Psujek H
Mult Scler Relat Disord; 2018 Nov; 26():204-206. PubMed ID: 30268042
[TBL] [Abstract][Full Text] [Related]
37. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study.
Mallucci G; Annovazzi P; Miante S; Torri-Clerici V; Matta M; La Gioia S; Cavarretta R; Mantero V; Costantini G; D'Ambrosio V; Zaffaroni M; Ghezzi A; Perini P; Rossi S; Bertolotto A; Rottoli MR; Rovaris M; Balgera R; Cavalla P; Montomoli C; Bergamaschi R
J Neurol; 2018 Aug; 265(8):1850-1859. PubMed ID: 29948245
[TBL] [Abstract][Full Text] [Related]
38. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
[TBL] [Abstract][Full Text] [Related]
39. Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison.
Chan A; Cutter G; Fox RJ; Xiao J; Lewin JB; Edwards MR
J Comp Eff Res; 2017 Jun; 6(4):313-323. PubMed ID: 28350241
[TBL] [Abstract][Full Text] [Related]
40. Dimethyl fumarate for treating relapsing multiple sclerosis.
Sheremata W; Brown AD; Rammohan KW
Expert Opin Drug Saf; 2015 Jan; 14(1):161-70. PubMed ID: 25382392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
